In this Phase III trial, the Padcev-Keytruda combination used as both neoadjuvant and adjuvant therapy significantly improved event-free and overall survival, as well as pathologic complete response, ...

Women with Down syndrome have more advanced signs of Alzheimer's disease than men do at the average age of diagnosis, which ...

Jason Bergsbaken, PharmD, MBA, BCOP, highlights the growing role of real-world data in validating or de-implementing therapies, the need for vigilant postapproval outcomes monitoring, and the value of ...

A medication developed in the 1950s to treat Parkinson's disease may offer a powerful new tool in the fight against tuberculosis (TB), according to ...

HIV-fighting antibodies produced in infant macaques in a preclinical trial could be the future of HIV prevention in humans, ...

International Myeloma Foundation Chief Medical Office Joseph Mikhael, MD, shares how the M-Power initiative is addressing ...

Discover six of the top psychedelic companies developing novel drugs to expand the treatment scope for mental health ...

Q2 2025 Earnings Call Transcript August 9, 2025 Operator: Good day, and thank you for standing by. Welcome to the Q2 2025 Ascendis Pharma Earnings Conference Call. [Operator Instructions] Please be ...

Q2 2025 Earnings Call Transcript August 8, 2025 Operator: Greetings, and welcome to the INmune Bio Second Quarter 2025 ...

Novartis' mAb ianalumab helped maintain safe platelet levels for a prolonged period, reducing patient reliance on hospital trips.

Topline results from pivotal Phase 3 INDIGO trial in Immunoglobulin G4-Related Disease expected around year-end 2025 - ...